Home › Funds › FRED ALGER MANAGEMENT, LLC › ARWR
FRED ALGER MANAGEMENT, LLC position in ARWR
ARROWHEAD PHARMACEUTICALS IN · Health Care
FRED ALGER MANAGEMENT, LLC reported holding 3,255,839 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$213.1M, representing 0.61% of its reported portfolio and ranking #33 among its reported holdings. FRED ALGER MANAGEMENT, LLC has disclosed ARWR holdings in 8 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How FRED ALGER MANAGEMENT, LLC's ARWR position evolved
FRED ALGER MANAGEMENT, LLC first disclosed a stake in ARWR in Q3 2023 at 46,419 shares (US$1.2M). The position peaked in Q2 2026 at 3,301,919 shares, worth US$269.1M. Across 8 filings, FRED ALGER MANAGEMENT, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,255,839 shares valued at US$213.1M — a reduction of -46,080 shares quarter over quarter.. Notable position changes include a 96% trim in Q1 2024 (shares fell 9% over the following quarter), a 497% increase in Q4 2025 (shares fell 6% over the following quarter), a 82% increase in Q1 2026 (shares rose 30% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 46.42K | $1.25M | New |
| Q4 2023 | 38.64K | $1.18M | Reduce |
| Q1 2024 | 1.54K | $44.13K | Reduce |
| Q3 2025 | 306.83K | $10.58M | New |
| Q4 2025 | 1.83M | $121.69M | Add |
| Q1 2026 | 3.34M | $209.57M | Add |
| Q2 2026 | 3.30M | $269.14M | Reduce |
| Q3 2026 | 3.26M | $213.09M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 37 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$720.0M), Vestal Point Capital, LP (US$315.1M), Siren, L.L.C. (US$149.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- Avoro Capital Advisors LLC 11.00M sh · $719.95M · Q3 2026
- Vestal Point Capital, LP 4.82M sh · $315.14M · Q3 2026
- Siren, L.L.C. 2.29M sh · $149.91M · Q3 2026
- BAKER BROS. ADVISORS LP 1.71M sh · $111.86M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 843.06K sh · $55.18M · Q3 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
More on FRED ALGER MANAGEMENT, LLC
FAQ
How long has FRED ALGER MANAGEMENT, LLC held ARWR?
FRED ALGER MANAGEMENT, LLC has disclosed ARWR holdings in 8 of the last 13 reported quarters, going back to Q3 2023.
What is FRED ALGER MANAGEMENT, LLC's current position in ARWR?
As of Q3 2026, FRED ALGER MANAGEMENT, LLC holds 3.26M shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $213.09M, representing 0.61% of its reported portfolio and ranking #33.
Has FRED ALGER MANAGEMENT, LLC been buying or selling ARWR?
In the latest 13F filing (Q3 2026), FRED ALGER MANAGEMENT, LLC reduced its position in ARWR. The position peaked in Q2 2026 at 3.30M shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, Vestal Point Capital, LP, Siren, L.L.C., among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.